Pfizer (PFE) Gross Margin (2009 - 2026)

Pfizer has disclosed Gross Margin across 18 years of filings, most recently posting 51.69% for Q1 2026.

• In Q1 2026, Gross Margin fell 1705.0% year-over-year to 51.69%; the TTM figure through Mar 2026 stood at 31.46% (down 2040.0% YoY), while the FY2025 annual figure was 74.33%, up 18714.0% from the prior year.
• Gross Margin fell to 51.69% in Q1 2026, from 69.97% in the prior quarter.
• Over the last five years, Gross Margin for PFE reached as high as 77.29% in Q1 2024 and fell as low as 1090.72% in Q3 2024.
• The 5-year median for Gross Margin is 34.64% (2025), against an average of 100.7%.
• Annual changes were most pronounced in 2024 — Gross Margin slumped 62726 bps — and 2025, when it surged 100917 bps.
• A 5-year view of Gross Margin shows it stood at 73.22% in 2022, then tumbled by 264 bps to 120.24% in 2023, then slumped by 807 bps to 1090.72% in 2024, then jumped by 106 bps to 69.97% in 2025, then tumbled by 174 bps to 51.69% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 51.69%, 69.97%, and 81.55% for Q1 2026, Q4 2025, and Q3 2025 respectively.